Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Maridebart Cafraglutide

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses

Amgen · Phase 1 · Not yet recruiting · Enrollment 356

NCT07921316

ArmPopulationDoseWeeksEstimandWeight change
Maridebart Cafraglutide: SC Presentation 1Obesity or overweightn/rn/rn/rn/r
Maridebart Cafraglutide: SC Presentation 2Obesity or overweightn/rn/rn/rn/r